$TLRY

Merton Carl A purchased $46K of TLRY

Merton Carl A (Chief Financial Officer) purchased 10,000 shares of Tilray Brands, Inc. (TLRY) at $4.62 on 2026-08-04.

Original reporting
SEC EDGAR · Merton Carl A
Published Aug 4, 2026, 5:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 4, 2026, 6:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TLRY
Neutral
medium confidence
Mentioned
$TLRY
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TLRYNeutralLow
01

Why it matters

The newest fact is the CFO’s open-market purchase details (10,000 shares at $4.62) filed on 2026-08-04; no other company-specific catalyst is included.

02

Market read

Traders may note the insider buy as a mild sentiment input, but the filing alone is unlikely to drive a durable repricing without additional fundamental news.

03

What to watch

The article provides no context on prior insider activity, option exercises, or whether the CFO has ongoing compensation-driven buying patterns.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-04 (same day as transaction)

Background

This is an SEC Form 4 insider transaction disclosure for Tilray Brands, Inc.

Company-level read

Ticker impact

$TLRYNeutralMedium confidence
Context

Tilray CFO Merton Carl A filed a Form 4 open-market purchase of 10,000 shares at $4.62 on 2026-08-04.

Expected impact

Likely limited near-term price impact; any effect is sentiment-driven and should fade unless followed by additional disclosures.

Evidence & confidence

Form 4 insider buys can be read as confidence, but the transaction size ($46.2k) is modest versus typical market-moving thresholds, and there is no accompanying guidance, deal, or regulatory event in the text.

Market effects

No sector-level implications are disclosed; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine liquidity or diversification actions, and the absence of a 10b5-1 plan does not guarantee a bullish fundamental thesis.

Key entities

  • Tilray Brands, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Merton Carl A

    Tilray CFO who purchased 10,000 shares open-market at $4.62.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TLRYMed

Jefferies raises Tilray stock price target on brewing restructuring

Jefferies raised its price target on Tilray Brands (TLRY) to $13 from $12, maintaining a Reduce rating. The stock trades at $2.67, down 80% over the past year. Tilray is restructuring its U.S. brewing operations, targeting $20 million in annual savings by 2028. The company reported $257.1 million in Q1 fiscal 2027 revenue, up 23% year-over-year, but posted a net loss of $40 million.

$TLRYMed

Tilray Medical Gains Approval For In-House Quality Testing At Portugal Facility

Tilray Brands (TLRY) received approval from Portugal's INFARMED for in-house quality testing at its Cantanhede facility. This allows microbiological and chemical/physical testing on-site, improving control and speeding up product release. The company expects reduced costs and faster supply to key markets like Germany and the UK. TLRY's stock closed at $3.36, down 5.08%, and was down 0.30% in premarket trading.

$TLRYMed

Tilray Brands, Inc.: Tilray Medical Strengthens Global Medical Cannabis Supply Chain with Approval to Bring Critical EU-GMP Quality Testing In-House, Accelerating Product Release Across Regulated Global Markets

Tilray Medical, a division of Tilray Brands (TLRY), received approval from Portugal's INFARMED to conduct in-house quality testing at its Cantanhede facility. This allows for faster product release and strengthens its global medical cannabis supply chain, benefiting markets like Germany and the UK. The move is expected to reduce costs and improve efficiency, supporting Tilray's position as a leading medical cannabis supplier.

$TLRYLow

Should you sell your Tilray stock?

Tilray Brands (TSX:TLRY) reported fiscal Q1 2027 revenue of $257.1M and Adjusted EBITDA of $9.2M, missing analyst estimates. Cannabis revenue fell 13% year-over-year, while beverage alcohol revenue rose 82.1%. Analyst Neal Gilmer maintained a 'Hold' rating and $4.00 target, citing concerns about organic growth and cash flow.